

## 8 Literaturverzeichnis

- Altieri, D. C. (2003): Survivin, versatile modulation of cell division and apoptosis in cancer, *Oncogene* 22 [53], Seite 8581-9.
- Ambrosini, G.; Adida, C. und Altieri, D. C. (1997): A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma, *Nat Med* 3 [8], Seite 917-21.
- Andersen, M. H.; Pedersen, L. O.; Becker, J. C. und Straten, P. T. (2001): Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients, *Cancer Res* 61 [3], Seite 869-72.
- Andersen, M. H. und Thor, S. P. (2002): Survivin--a universal tumor antigen, *Histol Histopathol* 17 [2], Seite 669-75.
- Avivi-Green, C.; Polak-Charcon, S.; Madar, Z. und Schwartz, B. (2002): Different molecular events account for butyrate-induced apoptosis in two human colon cancer cell lines, *J Nutr* 132 [7], Seite 1812-8.
- Blanc-Brude, O. P.; Mesri, M.; Wall, N. R., *et al.* (2003): Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis, *Clin Cancer Res* 9 [7], Seite 2683-92.
- Bug, G.; Ritter, M.; Wassmann, B., *et al.* (2005): Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia, *Cancer* 104 [12], Seite 2717-25.
- Canes, D.; Chiang, G. J.; Billmeyer, B. R., *et al.* (2005): Histone deacetylase inhibitors upregulate plakoglobin expression in bladder carcinoma cells and display antineoplastic activity in vitro and in vivo, *Int J Cancer* 113 [5], Seite 841-8.
- Chiou, S. K.; Jones, M. K. und Tarnawski, A. S. (2003): Survivin - an anti-apoptosis protein: its biological roles and implications for cancer and beyond, *Med Sci Monit* 9 [4], Seite PI25-9.
- Clarke, K. O.; Feinman, R. und Harrison, L. E. (2001): Tributyrin, an oral butyrate analogue, induces apoptosis through the activation of caspase-3, *Cancer Lett* 171 [1], Seite 57-65.
- Cordel, S.; Dupas, B.; Douillard, J. Y. und Meflah, K. (1998): Interleukin-2/sodium butyrate treatment cures rats bearing liver tumors after acquired 5-fluorouracil resistance, *Int J Cancer* 78 [6], Seite 735-9.
- Cress, W. D. und Seto, E. (2000): Histone deacetylases, transcriptional control, and cancer, *J Cell Physiol* 184 [1], Seite 1-16.

- De Schepper, S.; Bruwiere, H.; Verhulst, T., *et al.* (2003): Inhibition of histone deacetylases by chlamydocin induces apoptosis and proteasome-mediated degradation of survivin, *J Pharmacol Exp Ther* 304 [2], Seite 881-8.
- Donadelli, M.; Costanzo, C.; Faggioli, L., *et al.* (2003): Trichostatin A, an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells, *Mol Carcinog* 38 [2], Seite 59-69.
- Dovhey, S. E.; Ghosh, N. S. und Wright, K. L. (2000): Loss of interferon-gamma inducibility of TAP1 and LMP2 in a renal cell carcinoma cell line, *Cancer Res* 60 [20], Seite 5789-96.
- Fenrick, R. und Hiebert, S. W. (1998): Role of histone deacetylases in acute leukemia, *J Cell Biochem Suppl* 30-31, Seite 194-202.
- Fischer, C. und Oberneder, R. (2001): Nierenzellkarzinom, Interdisziplinäre Kurzgefaßte Leitlinien der Deutschen Krebsgesellschaft und der Deutschen Gesellschaft für Urologie Stand: 03.07.2006, Online im WWW unter URL: <http://www.uni-duesseldorf.de/WWW/AWMF/11/onko-037.htm>.
- Fisher, R. I.; Rosenberg, S. A. und Fyfe, G. (2000): Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma, *Cancer J Sci Am* 6 Suppl 1, Seite S55-7.
- Gayther, S. A.; Batley, S. J.; Linger, L., *et al.* (2000): Mutations truncating the EP300 acetylase in human cancers, *Nat Genet* 24 [3], Seite 300-3.
- Gilbert, J.; Baker, S. D.; Bowling, M. K., *et al.* (2001): A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies, *Clin Cancer Res* 7 [8], Seite 2292-300.
- Glaser, K. B.; Staver, M. J.; Waring, J. F., *et al.* (2003): Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines, *Mol Cancer Ther* 2 [2], Seite 151-63.
- Gore, S. D. und Carducci, M. A. (2000): Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors, *Expert Opin Investig Drugs* 9 [12], Seite 2923-34.
- Gottlicher, M.; Minucci, S.; Zhu, P., *et al.* (2001): Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells, *Embo J* 20 [24], Seite 6969-78.
- Green, D. R. und Evan, G. I. (2002): A matter of life and death, *Cancer Cell* 1 [1], Seite 19-30.
- Grossman, D.; Kim, P. J.; Schechner, J. S. und Altieri, D. C. (2001): Inhibition of melanoma tumor growth in vivo by survivin targeting, *Proc Natl Acad Sci U S A* 98 [2], Seite 635-40.

- Gu, W. und Roeder, R. G. (1997): Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain, *Cell* 90 [4], Seite 595-606.
- Hallscheidt, P. (2001): Nierenzellkarzinom, Kaufmann, G. W.; Moser, E. und Sauer, R., *Radiologie*, 2. Aufl., Seite 402-403, Urban&Fischer, München/Jena.
- Heerdt, B. G.; Houston, M. A.; Anthony, G. M. und Augenlicht, L. H. (1999): Initiation of growth arrest and apoptosis of MCF-7 mammary carcinoma cells by tributyrin, a triglyceride analogue of the short-chain fatty acid butyrate, is associated with mitochondrial activity, *Cancer Res* 59 [7], Seite 1584-91.
- Henderson, C.; Mizzau, M.; Paroni, G., *et al.* (2003): Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA), *J Biol Chem* 278 [14], Seite 12579-89.
- Hengartner, M. O. (2000): The biochemistry of apoptosis, *Nature* 407 [6805], Seite 770-6.
- Herold, C.; Ganslmayer, M.; Ocker, M., *et al.* (2002): The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells, *J Hepatol* 36 [2], Seite 233-40.
- Hetts, S. W. (1998): To die or not to die: an overview of apoptosis and its role in disease, *Jama* 279 [4], Seite 300-7.
- Kostyniuk, C. L.; Dehm, S. M.; Batten, D. und Bonham, K. (2002): The ubiquitous and tissue specific promoters of the human SRC gene are repressed by inhibitors of histone deacetylases, *Oncogene* 21 [41], Seite 6340-7.
- LaCasse, E. C.; Baird, S.; Korneluk, R. G. und MacKenzie, A. E. (1998): The inhibitors of apoptosis (IAPs) and their emerging role in cancer, *Oncogene* 17 [25], Seite 3247-59.
- Mahlknecht, U. und Hoelzer, D. (2000): Histone acetylation modifiers in the pathogenesis of malignant disease, *Mol Med* 6 [8], Seite 623-44.
- Mahotka, C.; Krieg, T.; Krieg, A., *et al.* (2002): Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas, *Int J Cancer* 100 [1], Seite 30-6.
- Mahotka, C.; Wenzel, M.; Springer, E.; Gabbert, H. E. und Gerharz, C. D. (1999): Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties, *Cancer Res* 59 [24], Seite 6097-102.
- Marks, P. A.; Richon, V. M.; Breslow, R. und Rifkind, R. A. (2001a): Histone deacetylase inhibitors as new cancer drugs, *Curr Opin Oncol* 13 [6], Seite 477-83.
- Marks, P.; Rifkind, R. A.; Richon, V. M., *et al.* (2001b): Histone deacetylases and cancer: causes and therapies, *Nat Rev Cancer* 1 [3], Seite 194-202.

- Martel, C. L. und Lara, P. N. (2003): Renal cell carcinoma: current status and future directions, *Crit Rev Oncol Hematol* 45 [2], Seite 177-90.
- Mirza, A.; McGuirk, M.; Hockenberry, T. N., *et al.* (2002): Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway, *Oncogene* 21 [17], Seite 2613-22.
- Motzer, R. J.; Michaelson, M. D.; Redman, B. G., *et al.* (2006a): Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma, *J Clin Oncol* 24 [1], Seite 16-24.
- Motzer, R. J.; Rini, B. I.; Bukowski, R. M., *et al.* (2006b): Sunitinib in patients with metastatic renal cell carcinoma, *Jama* 295 [21], Seite 2516-24.
- Oudard, S.; Levalois, C.; Andrieu, J. M., *et al.* (2002): Expression of genes involved in chemoresistance, proliferation and apoptosis in clinical samples of renal cell carcinoma and correlation with clinical outcome, *Anticancer Res* 22 [1A], Seite 121-8.
- Pandolfi, P. P. (2001): Transcription therapy for cancer, *Oncogene* 20 [24], Seite 3116-27.
- Park, W. H.; Jung, C. W.; Park, J. O., *et al.* (2003): Trichostatin inhibits the growth of ACHN renal cell carcinoma cells via cell cycle arrest in association with p27, or apoptosis, *Int J Oncol* 22 [5], Seite 1129-34.
- Pilatrino, C.; Cilloni, D.; Messa, E., *et al.* (2005): Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid, *Cancer* 104 [1], Seite 101-9.
- Rabelo, F. L.; Ramos, M. G.; Brumatti, G., *et al.* (2003): Apoptosis induced by butyrate is independent of Jak/STAT signaling in a fibrosarcoma cell line, *Biochem Biophys Res Commun* 301 [4], Seite 968-73.
- Ratain, M. J.; Eisen, T.; Stadler, W. M., *et al.* (2006): Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma, *J Clin Oncol* 24 [16], Seite 2505-12.
- Reid, T.; Valone, F.; Lipera, W., *et al.* (2004): Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer, *Lung Cancer* 45 [3], Seite 381-6.
- Ruefli, A. A.; Ausserlechner, M. J.; Bernhard, D., *et al.* (2001): The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species, *Proc Natl Acad Sci U S A* 98 [19], Seite 10833-8.

- Siemer, S. (2006): Nierenzellkarzinom, Preiß, J. ; Dornoff, W.; Hagmann, F.-G. und Schmieder, A., Interdisziplinäre Empfehlungen zur Therapie 2006/07, 13. Aufl., Seite 182-184, W. Zuckschwerdt Verlag, München/Wien/New York.
- Takai, N.; Desmond, J. C.; Kumagai, T., *et al.* (2004): Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells, *Clin Cancer Res* 10 [3], Seite 1141-9.
- Tyagi, A. K.; Agarwal, C.; Singh, R. P., *et al.* (2003): Silibinin down-regulates survivin protein and mRNA expression and causes caspases activation and apoptosis in human bladder transitional-cell papilloma RT4 cells, *Biochem Biophys Res Commun* 312 [4], Seite 1178-84.
- Velculescu, V. E.; Madden, S. L.; Zhang, L., *et al.* (1999): Analysis of human transcriptomes, *Nat Genet* 23 [4], Seite 387-8.
- Warrell, R. P., Jr.; He, L. Z.; Richon, V.; Calleja, E. und Pandolfi, P. P. (1998): Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase, *J Natl Cancer Inst* 90 [21], Seite 1621-5.
- Werner, N. S.; Siprashvili, Z.; Fong, L. Y., *et al.* (2000): Differential susceptibility of renal carcinoma cell lines to tumor suppression by exogenous Fhit expression, *Cancer Res* 60 [11], Seite 2780-5.
- Williams, N. S.; Gaynor, R. B.; Scoggin, S., *et al.* (2003): Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference, *Clin Cancer Res* 9 [3], Seite 931-46.
- Zornig, M.; Hueber, A.; Baum, W. und Evan, G. (2001): Apoptosis regulators and their role in tumorigenesis, *Biochim Biophys Acta* 1551 [2], Seite F1-37.